Clinical trials: sponsored by AbbVie
Healthy Volunteer
A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants
This study will assess the effect of food (high fat) on oral ABBV-101 and how ABBV-101 moves through the body in healthy adult participants
- Trial name
- NCT06887010
- Testing
- ABBV-101
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- AbbVie
Alzheimer Disease
A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants
This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of intravenously (IV) or subcutaneously (SC) injected…
- Trial name
- NCT06406348
- Testing
- ALIA-1758
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants
This study will assess the relative bioavailability of two different Oral formulations of tavapadon in healthy adult participants.
- Trial name
- NCT06895356
- Testing
- Tavapadon
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers
The main objective of this study is to evaluate the dopamine D2 and D3 receptor occupancy in the brain as measured by PET with radiotracer [11C]-(+)-PHNO up to 14 days of once-daily oral doses of ABBV-932 in healthy subjects.
- Trial name
- Ph1PET UK Stdy (NCT06300580)
- Testing
- ABBV-932
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers
The main objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of single subcutaneous (SC) and intravenous (IV) doses of ABBV-382 in healthy adult Chinese volunteers.
- Trial name
- NCT06632938
- Testing
- ABBV-382
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants
This study will assess the pharmacokinetics, relative bioavailability and tolerability of two formulations of risankizumab following subcutaneous (SC) administration in healthy adult participants.
- Trial name
- NCT06571266
- Testing
- Risankizumab
- Where
- 3 sites in United States
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Participants, Alzheimer's Disease Dementia
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
The primary purpose of the study is to evaluate the safety and tolerability of emraclidine administered orally to healthy elderly participants in Part A (multiple ascending doses) and participants with dementia due to Alzheimer's…
- Trial name
- NCT05644977
- Testing
- Emraclidine
- Where
- 11 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- AbbVie
Hepatic Impairment
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
The primary purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe hepatic…
- Trial name
- NCT05935033
- Testing
- Emraclidine
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- AbbVie
Renal Impairment
A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function
The primary purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe renal…
- Trial name
- NCT05940402
- Testing
- Emraclidine
- Where
- 5 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers, Generalized Anxiety Disorder (GAD)
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder…
- Conditions
- Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
- Trial name
- MAD (NCT06024239)
- Testing
- ABBV-932
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.
This study will assess the single dose safety, tolerability and pharmacokinetic properties of ABBV-1088 in healthy adult participants
- Trial name
- NCT06414798
- Testing
- Drug: ABBV-1088
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
The objective of this study is to compare pharmacokinetic exposures following intravenous and subcutaneous administration of Risankizumab.
- Trial name
- NCT06487572
- Testing
- Risankizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants
This study will assess the pharmacokinetics, safety, and tolerability of icalcaprant administered orally in healthy adult Japanese and Han Chinese participants.
- Trial name
- 528 Asian PK (NCT06722417)
- Testing
- Icalcaprant
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants
This study is to assess the change of itraconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety, and tolerability of a single dose of icalcaprant in healthy participants.
- Trial name
- 529 DDI ITZ (NCT06722430)
- Testing
- Icalcaprant, Itraconazole (ITZ)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity after single ascending doses (SAD) of ABBV-141 in healthy adult Western and Asian participants.
- Trial name
- NCT06148181
- Testing
- ABBV-141
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe
The objective of this study is to assess the pharmacokinetics, immunogenicity, safety, and tolerability, of subcutaneous formulation of ravagalimab in a pre-filled syringe in healthy adult participants.
- Trial name
- NCT06402513
- Testing
- Ravagalimab
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants
The objectives of this study are to assess safety and tolerability of the new ABBV-668 ER tablets, to assess the oral bioavailability of the ABBV-668 ER tablets relative to the ABBV-668 IR capsules, and to assess the…
- Trial name
- NCT06477926
- Testing
- ABBV-668 IR, ABBV-668 ER
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers
The purpose of this study is to evaluate the relative bioavailability of three immediate-release table formulations of ABBV-903 under fasting conditions in healthy volunteers, and to evaluate the effect of food on the…
- Trial name
- NCT06078202
- Testing
- ABBV-903
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- AbbVie
Generalized Anxiety Disorder (GAD), Healthy Participants
Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants
The main objective of this study is to assess pharmacokinetics, safety, and tolerability of ABBV-932 in healthy adult participants.
- Trial name
- NCT05738850
- Testing
- ABBV-932
- Where
- 2 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants
The purpose of this study is to assess the bioavailability of two different doses of venetoclax new high drug load formulation tablets relative to two tablets of the currently marketed venetoclax tablets under fed conditions.
- Trial name
- NCT06070948
- Testing
- Venetoclax
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- AbbVie